The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
If it's below low end and minimum as forecast isn't met, there's every chance the SP will take a hit. - The last report indicated on track to meet forecast parameters. - Any subsequent impediment/set-back against achieving this would have had to be reported I think. - It hasn't been, so there is every reason to be optimistic.
This really is mortgaging the future isn't it. - Of course they already have an IMF liability to cope with. - I wonder where funds will come from when the bonds mature in x years time. - That problem is for then I suppose, the immediate problem is maintaining life & limb for now. - Suez canal and oil& gas assets dwarf Centamins role I would suggest. - It'll be interesting to learn the details. - I'll be surprised if Saudi Arabia doesn't figure prominently in the new Monopoly game and possibly even China. - IMO
Some may find this interesting:
https://www.msn.com/en-gb/money/other/endeavour-mining-boss-sacked-over-5m-payment/ar-AA1muVrG?ocid=msedgntp&cvid=3f4b872dfe4043258985516ccaad549e&ei=23
Exactly Beuna Vista - That's why I made a point of it. - The financial position is a part of today's announcement and therefore worthy of reflection/comment. - Just reflecting on facts, not fantasy/sentiment.
sajy - Your crystal ball is broken. - I haven't sold my shares and I'm very happy to hang on to them for now and possibly add if my judgement allows. - Are you normally as aggressive and as assertive?
Good to have positive news for a change although my jaded-Centamin view will remain on red-alert for now. - I'd like to get 2023 out of the way without an RNS informing of production set-backs. - A few days still to go. - I hope this isn't a set-up to cushion bad news. - Paranoid or what? :)
I'm new here as you will have gathered - I expressed my gratitude to sajy on the basis of him taking the trouble to communicate with the company and having the generosity of sharing the experience. - Not many take the trouble to do this. - One big plus for me going forward has nothing to do with the drugs/treatments being developed, but rather the fact that they have no-debt. - Into 2024 and I'm expecting some big-shocks linked to the debt-burdens being carried by some well-known companies. - So, no debt a big plus for me.